T

TC BioPharm Ltd
NASDAQ:TCBP

Watchlist Manager
TC BioPharm Ltd
NASDAQ:TCBP
Watchlist
Price: 0.5 USD -67.53% Market Closed
Market Cap: 63k USD

TCBP's latest stock split occurred on Feb 10, 2025

The company executed a 1-for-20 stock split, meaning that for every 20 shares held, investors received 1 new share.

Before the split, TCBP traded at 0.2015 per share. Afterward, the share price was about 3.8.

The adjusted shares began trading on Feb 10, 2025. This was TCBP's 5th stock split, following the previous one in Jan 7, 2025.

Last Splits:
Feb 10, 2025
1-for-20
Jan 7, 2025
5-for-4
Aug 5, 2024
1-for-10
Dec 15, 2023
1-for-20
Nov 21, 2022
1-for-50
Pre-Split Price
4.03 0.2015
Post-Split Price
3.8
Before
After
Last Splits:
Feb 10, 2025
1-for-20
Jan 7, 2025
5-for-4
Aug 5, 2024
1-for-10
Dec 15, 2023
1-for-20
Nov 21, 2022
1-for-50

TC BioPharm Ltd
Stock Splits History

TCBP Stock Splits Timeline
Feb 10, 2025
Feb 10, 2025
Split 1-for-20
/0.05
Pre-Split Price
4.03 0.2015
Post-Split Price
3.8
Before
After
Jan 7, 2025
Jan 7, 2025
Split 5-for-4
x1.25
Pre-Split Price
8.0544 0.5034
Post-Split Price
8.32
Before
After
Aug 5, 2024
Aug 5, 2024
Split 1-for-10
/0.1
Pre-Split Price
69.12 0.432
Post-Split Price
67.36
Before
After
Dec 15, 2023
Dec 15, 2023
Split 1-for-20
/0.05
Pre-Split Price
476.8 0.149
Post-Split Price
412.8
Before
After
Nov 21, 2022
Nov 21, 2022
Split 1-for-50
/0.02
Pre-Split Price
25 760.0164 0.161
Post-Split Price
20 960.0003
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Jan 20, 2026
Linius Technologies Ltd
OTC:LNNTF
1-for-100
/100
0.0001 0.0001 USD N/A
Jan 20, 2026
Lotus Resources Ltd
OTC:LTSRF
1-for-11
/11
0.1377 0.1377 USD N/A
Jan 15, 2026
Amcor PLC
NYSE:AMCR
1-for-5
/5
8.57 8.57 USD N/A
Jan 8, 2026
Sumitomo Realty & Development Co Ltd
OTC:SURYY
2-for-1
x2
25.635 25.635 USD N/A
Jan 7, 2026
Deutsche Effecten und Wechsel Beteiligungsgesellschaft AG
SWB:EFF
1-for-10
/10
0.35 0.35 EUR N/A
Load More

TC BioPharm Ltd
Glance View

Market Cap
63k USD
Industry
Biotechnology

TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The firm is engaged in developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. The firm's platform technology allows Company's to design specific therapies to treat a range of cancers and infectious diseases with off the shelf allogeneic gamma delta T cell (GDT) products. The Company’s pipeline includes OmnImmune, ImmuniStim and CAR-T programs. OmnImmune is an unmodified allogeneic gamma delta T cell product, being used for the treatment of acute myeloid leukemia (AML). ImmuniStim is an unmodified allogeneic gamma delta T cell product, being used for the treatment of COVID-19. The firm also provides in-house and partner programs at the pre-clinical stage focused on developing CAR modified allogeneic gamma delta T-cell products targeting solid and hematological indications.

TCBP Intrinsic Value
Not Available
T
Back to Top